New method for asymmetric N,N-acetal synthesis promises advances in drug development

0

Scientists identify new method of preparing N,N-acetals with high enantiopurity using diketones, crowning a new approach to synthesizing bioactive drugs

IMAGE

Credit: Picture courtesy: Shuichi Nakamura from NITech

A lot of our medicines and other bioactive drugs are based on chemical structures called “enantiomers”– molecules that are mirror images of each other and are non-superimposable. Notable among them are chiral N,N-acetals contained in diuretic drugs like bendroflumethiazide and thiabutazide, used to treat high blood pressure and edema. Because an enantiomer and its mirror image version often have different biological activities, with only one of them having pharmacological utility, an “enantioselective” or asymmetric synthesis yielding the desired enantiomer in greater amounts is highly desirable.

In the case of N,N-acetals, several studies have demonstrated their enantioselective preparation from aldehydes, aldimines, or enamines. However, in all these cases, their reaction partner has been limited to aldehyde or imines. While ketones have been employed, with instances of successful enantioselective N,N-acetal synthesis, their use–in general–is not considered effective.

In a recent study published in Advanced Synthesis & Catalysis, scientists from Nagoya Institute of Technology (NITech) and Osaka University in Japan explored this situation with an enantioselective synthesis of chiral N,N-acetals from α-dicarbonyl compounds–compounds with two carbonyl (ketone) groups on the α-carbon–in presence of chiral imidazoline phosphoric acid catalysts, and obtained yields as high as 99% with a maximum enantiopurity of 96%.

“Our study presents the first highly stereoselective formation of chiral N,N-acetals from α-ketoesters using an original catalyst that can be used for other stereoselective synthetic reactions as well,” says Prof. Shuichi Nakamura from NITech, who led the study.

The scientists began by examining the reaction of 2-aminobenzamide with various α-ketoesters in presence of different catalysts. The α-ketoesters differed from one another in the nature of the functional group attached to the α-carbon, while the catalysts chosen were bis(imidazoline)-phosphoric acid with different substituents attached to the nitrogen in the imidazoline ring, mono-imidazoline-phosphoric acid, and two commercial chiral phosphoric acids. Among these various combinations, scientists found the best yield (99%) and enantiopurity (92%) in the case of α-ketoester with benzhydryl group and a bis(imidazoline)-phosphoric acid catalyst with 1-naphthalenesulfonyl group.

Scientists next examined the reaction of various aminobenzamides (bearing either an electron-donating methyl group or electron-withdrawing fluoro, chloro, and bromo groups) with different α-ketoesters (containing the same benzhydryl group but different functional groups in place of an earlier phenyl group) keeping the same bis(imidazoline)-phosphoric acid catalyst with 1-naphthalenesulfonyl group. All the combinations showed good yield (77-95%) along with high enantioselectivity (82-96%).

In addition, the team looked at the enantioselective synthesis of N,N-acetals via the reaction of N-benzyl isatin (a cyclic α-ketoamide), benzil (an acyclic diketone), and benzaldehyde with 2-aminobenzamide for the same catalyst. All three reactions yielded products with high enantiopurity (91-93%).

The team also proposed a possible mechanism for the N,N-acetal formation reaction corresponding to the best yield (99%), involving a ketimine intermediate with an amide group that helps avoid steric repulsion between the phenyl group on imidazoline, enabling the formation of an (R)-isomer with high enantiopurity.

While the mechanism is still speculative and requires further investigation, scientists are excited about the potential implications of the experimental results. “Our new method will enable the synthesis of candidate pharmaceutical drugs that are currently difficult to synthesize, and can even potentially help create and provide people with new and better medicines in the future,” concludes Prof. Nakamura.

Now, those are some promising consequences to look forward to!

###

This study was made available online in October 2020 ahead of final publication in issue on December 8, 2020.

About Nagoya Institute of Technology, Japan

Nagoya Institute of Technology (NITech) is a respected engineering institute located in Nagoya, Japan. Established in 1949, the university aims to create a better society by providing global education and conducting cutting-edge research in various fields of science and technology. To this end, NITech provides a nurturing environment for students, teachers, and academicians to help them convert scientific skills into practical applications. Having recently established new departments and the “Creative Engineering Program,” a 6-year integrated undergraduate and graduate course, NITech strives to continually grow as a university. With a mission to “conduct education and research with pride and sincerity, in order to contribute to society,” NITech actively undertakes a wide range of research from basic to applied science.

Website: https://www.nitech.ac.jp/eng/index.html

About Dr. Shuichi Nakamura from Nagoya Institute of Technology, Japan

Dr. Shuichi Nakamura is Professor at the Department of Life and Materials Chemistry at Nagoya Institute of Technology (NITech), Japan. He studied organic chemistry at NITech, where he received his PhD in 2001 and joined as Assistant Professor in the same year. His current research interests include asymmetric reactions and asymmetric catalysts. He has received the Inoue Research Award for Young Scientists (2001) for his Ph. D. thesis and several others. He has 145 publications to his credit with over 6000 citations and has co-authored 7 books.

Media Contact
Azusa Yabugami
[email protected]

Original Source

https://www.nitech.ac.jp/eng/news/2021/8715.html

Related Journal Article

http://dx.doi.org/10.1002/adsc.202001128

Leave A Reply

Your email address will not be published.